After five years of construction and an investment of US$470 million, the new base fractionation “Phoenix” starts regular operation. This is a testament to our commitment to deliver on our promise to patients.
The new proverbial heart of our production line has come to life: the base fractionation in Marburg has been ceremonially opened. With optimized process flows, modern technologies, and an increased degree of automation the new state-of-the-art base fractionation in Marburg quadruples the current capacity to fractionate blood plasma. On an area of 10,000 m², the team worked up to 4,500 hours every day to complete the mega project in time.
Michael Schröder, Vice President, Site Leader and Managing Director at the Marburg site reflects on the accomplishment: “The Phoenix project is characterized by two components. Firstly, the state-of-the-art technology, but secondly, and more importantly for me, the great team that has made it possible to celebrate this milestone today.”
Markus Ries, Value Stream Lead Base Fractionation and Lead of the Phoenix Project also sees the team effort as key to the successful completion of the project: “Even though there have been occasional obstacles in our way, such as the pandemic, the team’s unspeakable belief in the project and the will to succeed have made it possible to overcome them.“
The new facility in Marburg plays an important role in leveraging the network for a stronger CSL family, especially with the simultaneous construction of a sister facility sporting identical equipment and processes in Broadmeadows, Australia. They serve as prime examples for cross-functional and cross-cultural development opportunities for the company and its employees.
